What changed
$DHR — Manufactures scientific instruments and diagnostic products.
🎯 Q1 FY26 | Rev $6B | EPS $2.06 vs $1.94 🟢 | Margin 24.1%
💡 Consensus expects DHR to grow EPS ~7% in FY2026 to $8.44, but the guidance raise to $8.35-$8.55 is only a modest bump at the midpoint ($8.45 vs prior $8.425). The market may be overreacting to a 6.5% EPS beat in Q1, which was driven by cost control (flat revenue YoY) and buybacks (shares down 1.3%).
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 16% to $210 (25x FY2026 EPS of $8.44) vs downside 17% to $150 (18x FY2026 EPS). Ratio ~0.9:1, not compelling for a 3-month horizon.
🔮 Catalyst: Q2 2026 earnings (late July 2026): Revenue growth inflection is the key metric. Consensus expects ~$6.27B (+5.3% YoY). If DHR reports revenue growth above 5% and maintains/raises guidance, the stock could re-rate.
Also in play: $CNC $HUM $UNH $CI $ELV $MCK